Business Context and Reporting Period
This Form 8-K was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on April 24, 2020. The company, incorporated in Delaware, operates a dual business strategy involving licensing/collaboration (UniverCyte and PureStem platforms) and in-house product development (VASC1, BAT1, and iTR technology). The filing addresses strategic adjustments made by the Board of Directors in response to capital market conditions and the COVID-19 pandemic.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific financial figures disclosed relate solely to the restructuring event:
- Accrued Payroll and Benefits: Approximately $105,000.
- Restructuring Charges: Approximately $194,800 (consisting of contractual severance and termination benefits).
- Settlement Method: Substantially all charges are expected to be settled in cash.
Material Changes
On April 24, 2020, the Board of Directors initiated a reduction in force affecting 12 employees, primarily within research and development. This action is expected to be completed on or around May 1, 2020. Consequently, the company will defer in-house work on its therapy product candidates and iTR technology. Some development work may be outsourced pending future financing or research grants.
Outlook, Risks, and Management Commentary
Management states that these adjustments are necessary to reduce projected cash expenditures and extend the operational runway with available resources. The company notes that development of its iTR technology may continue at its subsidiary, Reverse Bioengineering, Inc., subject to successful financing of that subsidiary. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risk factors detailed in periodic SEC reports.
Investor Verification Checklist
- Verify the total cash impact of the $194,800 restructuring charge and $105,000 accrued benefits on the company's current liquidity.
- Confirm the status of the subsidiary, Reverse Bioengineering, Inc., and its ability to secure financing for iTR technology development.
- Monitor upcoming filings for details on the deferral of VASC1 and BAT1 product development timelines.
- Review the company's capital raising efforts to rebuild the R&D staff as mentioned in the filing.